This $5,666,172 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at New York University (NYU) and collaborating institutions to investigate novel targets for treating chemotherapy-induced painful peripheral neuropathy (CIPPN).
The key research activities under this 5-year award include:
- Examining the role of the PPAR-gamma and LRP1 signaling pathway in regulating Schwann cell survival, bioenergetics, and inflammation in response to chemotherapeutic agents
- Studying the effects of PPAR-gamma and LRP1 agonists on chemotherapy-induced oxidative stress, neuroinflammation, and changes in sensory neuron excitability using in vitro and in vivo models
- Validating the research findings in human Schwann cells, nerves, and co-culture systems with dorsal root ganglion neurons
The project involves collaborations between NYU and subgrantees at the University of California, San Diego and the University of New Mexico Health Sciences Center.
Generated 3/4/25, 1:56 AM